Despite efforts to solve its credit woes, Impel Pharmaceuticals is still staring down the barrel of bankruptcy, launching a last-ditch attempt to save itself and search for strategic alternatives, including a potential sale.
Impel Pharmaceuticals’ money miseries have left it looking to lenders for leniency. In breach of a credit agreement, the developer of intranasal drugs has warned it may have to sell assets or file for bankruptcy if it is unable to restructure its deal and secure fresh funding.
Real-World Assessment Suggests that Concomitant Preventive and Acute Medication Use Decreases in Patients Using Trudhesa Additional Poster Underscores the Need for Non-Oral Treatment Options Given...
Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor...
SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering...
SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases...
Impel Pharmaceuticals Presents New Data at AAN 2023 Suggesting Trudhesa® Nasal Spray is Safe to Use When Co-Administered With Commonly Prescribed Migraine Medications
Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors
Impel Pharmaceuticals to Present Data on Trudhesa® Nasal Spray for Treatment of Acute Migraine at 2023 American Academy of Neurology Annual Meeting